idiopath
pulmonari
fibrosi
ipf
common
form
interstiti
pneumonia
unknown
caus
chronic
progress
fibrot
process
limit
lung
occur
primarili
older
adult
associ
histopatholog
radiolog
pattern
usual
interstiti
pneumonia
uip
diagnosi
ipf
requir
exclus
form
interstiti
pneumonia
especi
associ
occupationalenvironment
exposur
medic
system
diseas
although
median
surviv
year
time
diagnosi
high
variabl
evolut
ipf
one
patient
anoth
differ
period
time
given
individu
therefor
predict
outcom
ipf
challeng
major
progress
made
recent
year
particular
effort
identifi
patient
highest
risk
diseas
progress
might
benefit
treatment
intervent
clinic
phenotyp
differ
surviv
identifi
overal
poorer
prognosi
associ
older
age
year
smoke
histori
low
bodi
mass
index
sever
physiolog
impair
larg
radiolog
extent
diseas
presenc
pulmonari
hypertens
patient
ipf
gener
rel
slow
progress
clinic
cours
often
refer
pulmonari
specialist
month
year
onset
symptom
present
lung
physiolog
display
restrict
pattern
usual
forc
vital
capac
fvc
predict
valu
without
hypoxemia
rest
worsen
exercis
cours
diseas
progress
often
unpredict
decreas
fvc
often
linear
diagnosi
made
predict
valu
fvc
lower
predict
invari
associ
death
within
week
month
besid
typic
pattern
chronic
progress
diseas
subgroup
patient
mainli
male
cigarett
smoker
rapidli
progress
cours
associ
shorter
surviv
known
acceler
ipf
despit
similar
present
time
diagnosi
patient
ipf
may
also
experi
acut
respiratori
deterior
mani
acut
declin
idiopath
ie
without
identifi
caus
infect
left
heart
failur
pulmonari
embol
etc
episod
idiopath
acut
deterior
term
acut
exacerb
ae
ipf
acceler
ipf
aeipf
occur
success
patient
suggest
differ
ipf
phenotyp
may
repres
acceler
underli
fibroprolif
disord
contrast
ae
asthma
chronic
obstruct
pulmonari
diseas
aeipf
design
idiopath
acut
worsen
progress
fibrosi
articl
review
definit
pathophysiolog
clinic
diagnost
therapeut
issu
relat
aeipf
kondoh
et
al
describ
acut
clinic
deterior
three
ipf
patient
acut
influenzalik
symptom
cough
fever
leukocytosi
progress
hypoxia
develop
absenc
identifi
infect
histolog
find
openlung
biopsi
show
uip
organ
acut
lung
injuri
pattern
recent
collard
et
al
consensu
statement
aim
give
standard
definit
event
acut
clinic
signific
deterior
unidentifi
caus
patient
underli
ipf
distinct
acut
respiratori
worsen
relat
known
caus
criteria
consensu
definit
aeipf
list
tabl
criteria
may
lack
patient
clinic
worsen
day
patient
hrct
bronchoalveolar
lavag
bal
perform
ipf
patient
clinic
worsen
unknown
caus
fulfil
criteria
consid
suspect
aeipf
event
nevertheless
relev
practic
possibl
clinic
trial
acut
exacerb
restrict
ipf
may
also
complic
cours
interstiti
lung
diseas
includ
nonspecif
interstiti
pneumonia
connect
tissu
diseasesrel
interstiti
lung
diseas
mainli
rheumatoid
arthriti
hypersensit
pneumon
acut
worsen
sarcoidosi
describ
seem
compar
aeipf
although
aeipf
consid
idiopath
event
find
diffus
alveolar
damag
dad
suggest
acut
injuri
insult
histolog
similar
fibroprolif
ard
howev
present
patient
fever
flulik
symptom
neutrophilia
bal
fluid
specimen
plausibl
implic
unrecogn
infecti
etiolog
wootton
et
al
observ
patient
aeipf
presenc
common
respiratori
viral
infect
parainfluenza
rhinoviru
coronaviru
convers
virus
detect
bal
stabl
patient
furthermor
panvir
microarray
reveal
addit
evid
viral
infect
herp
simplex
viru
viru
torqu
teno
viru
ttv
patient
aeipf
ttv
infect
significantli
common
patient
acut
exacerb
stabl
control
present
similar
percentag
diseas
control
acut
lung
injuri
deep
sequenc
subset
acut
exacerb
case
confirm
presenc
ttv
identifi
addit
virus
furthermor
detect
elev
pepsin
level
bal
aeipf
patient
suggest
aspir
could
respons
occurr
aeipf
subgroup
patient
consist
result
treatment
proton
pump
inhibitor
significantli
reduc
incid
aeipf
anoth
subgroup
patient
occurr
aeipf
may
caus
increas
mechan
stress
lung
may
secondari
surgeri
lung
biopsi
lung
resect
nonrespiratori
surgeri
bal
prolong
mechan
ventil
high
tidal
volum
high
concentr
supplement
oxygen
surgeri
suggest
potenti
caus
recent
studi
indic
ambient
air
pollut
may
also
caus
aeipf
particularli
ozon
nitrogen
dioxid
final
drug
may
respons
occurr
aeipf
includ
biolog
anakinra
etanercept
infliximab
nonbiolog
ambrisentan
agent
immunomodulatori
everolimu
interferon
alpha
beta
antineoplast
agent
convent
chemotherapi
new
drug
tyrosin
kinas
inhibitor
potenti
caus
drug
suggest
differ
caus
pathway
may
respons
occurr
aeipf
differ
patient
molecular
mechan
relat
condit
also
poorli
known
recent
studi
emphas
role
immunolog
regul
fact
shown
annexin
autoantigen
abl
induc
humor
cellular
immunolog
respons
patient
aeipf
ntermin
portion
annexin
play
role
pathogenesi
condit
reduc
express
heat
shock
protein
collagenspecif
molecular
chaperon
essenti
synthesi
secret
collagen
reduc
collagen
product
fibrosi
progress
serum
level
significantli
higher
aeipf
stabl
ipf
suggest
role
molecul
aeipf
pathogenesi
furthermor
express
greater
dad
uip
tissu
consist
result
ipf
patient
autoantibodi
nearterm
lung
function
impair
mortal
compar
neg
ipf
patient
anoth
studi
famili
mammalian
neutrophil
peptid
variou
biolog
among
upregul
gene
aeipf
gene
express
microarray
analysi
correspond
peripher
blood
protein
level
elev
patient
aeipf
absenc
infect
furthermor
serum
level
protein
member
famili
express
mainli
thelper
cell
induc
proinflammatori
protein
tumor
necrosi
factor
tnf
alpha
andor
beta
also
significantli
higher
patient
aeipf
control
howev
shown
collard
et
al
studi
detect
plasma
biomark
profil
aeipf
compar
profil
stabl
ipf
ard
aeipf
character
increas
type
ii
alveolar
epitheli
cell
injuri
prolifer
marker
kreb
von
den
lunden
surfact
protein
sp
endotheli
cell
injuri
marker
ie
von
willebrand
factor
coagul
abnorm
protein
c
thrombomodulin
plasminogen
activ
inhibitor
pai
interestingli
littl
evid
role
type
alveolar
epitheli
cell
injuri
substanti
acut
inflamm
report
incid
aeipf
vari
wide
among
studi
recogn
rel
common
event
data
placebo
arm
larg
clinic
trial
find
incid
aeipf
period
year
incid
lower
anoth
trial
anoth
random
control
trial
anticoagul
therapi
ipf
involv
patient
follow
approxim
year
rehospit
aeipf
die
note
subject
initi
enrol
studi
admiss
hospit
suggest
studi
popul
enrich
prior
episod
aeipf
rapidli
progress
diseas
incid
aeipf
may
vari
greatli
sever
diseas
delay
sinc
diagnosi
ipf
diagnost
criteria
use
effort
made
rule
infect
illustr
data
recent
highqual
ipf
trial
half
case
acut
deterior
suspect
investig
aeipf
eventu
confirm
aeipf
adjud
committe
although
data
trial
inform
particip
gener
select
earli
rather
advanc
diseas
possibl
low
progress
diseas
compar
gener
ipf
popul
therefor
possibl
underestim
frequenc
aeipf
nevertheless
somewhat
compar
result
obtain
retrospect
review
observ
cohort
patient
biopsyproven
ipf
meet
criteria
aeipf
incid
ae
aeipfrel
mortal
incid
aeipf
studi
biopsyconfirm
diagnosi
ipf
may
differ
ipf
diagnos
without
biopsi
due
potenti
select
bia
time
first
visit
onset
aeipf
rang
month
retrospect
design
studi
may
underestim
incid
rate
addit
case
acut
worsen
could
includ
due
miss
data
southkorean
studi
suggest
potenti
higher
mortal
asian
popul
compar
caucasian
patient
might
link
genet
suscept
mortal
may
vari
howev
diagnost
criteria
use
popul
studi
comorbid
potenti
genet
factor
time
mortal
assess
whether
earlier
diagnosi
manag
might
improv
outcom
unknown
recent
larger
retrospect
studi
patient
ipf
biopsi
proven
group
incid
aeipf
respect
use
differ
approach
martinez
et
al
evalu
clinic
cours
patient
mild
moder
ipf
found
appar
acut
clinic
deterior
preced
death
patient
die
ipf
autopsi
find
also
show
ae
common
immedi
caus
death
patient
ipf
collect
observ
suggest
incid
aeipf
may
underestim
ipf
clinic
trial
may
repres
signific
proport
lethal
event
sever
risk
factor
aeipf
identifi
ae
may
occur
time
cours
ipf
although
common
patient
progress
diseas
declin
fvc
month
baselin
clear
associ
age
smoke
histori
may
protect
aeipf
although
aeipf
appear
common
male
data
conflict
regard
smoke
one
studi
comparison
clinic
featur
ipf
patient
without
aeipf
show
differ
age
smoke
statu
oxygen
lung
function
time
diagnosi
ambient
air
pollut
particularli
increas
exposur
ozon
nitrogen
dioxid
eman
larg
motor
vehicl
increas
risk
aeipf
pulmonari
hypertens
time
evalu
lung
transplant
increas
risk
subsequ
ae
ipf
like
endotheli
dysfunct
data
sever
studi
suggest
season
variat
aeipf
increas
frequenc
winter
month
patient
histori
aeipf
higher
risk
subsequ
aeipf
event
gastroesophag
reflux
also
risk
factor
aeipf
administr
proton
pump
inhibitor
significantli
reduc
incid
aeipf
pepsin
level
marker
gastric
aspir
elev
bal
fluid
patient
aeipf
compar
obtain
stabl
diseas
symptomat
reflux
may
explain
higher
risk
ae
patient
asymmetr
ipf
sever
observ
suggest
patient
undergo
surgic
lung
biopsi
even
surgic
procedur
organ
lung
may
higher
risk
aeipf
although
distinguish
case
postsurg
acut
respiratori
distress
syndrom
difficult
exact
mechan
surgic
procedur
may
trigger
ae
present
unknown
patient
sever
diseas
particularli
low
dlco
requir
mechan
ventil
seem
higher
risk
ae
surgeri
case
report
aeipf
develop
bal
procedur
howev
number
case
bal
lung
biopsi
may
perform
subject
alreadi
acceler
cours
diseas
would
prone
develop
aeipf
aeipf
also
observ
patient
receiv
chemotherapi
lung
cancer
immedi
postop
period
lung
resect
lung
cancer
follow
radiotherapi
ae
report
patient
syndrom
combin
pulmonari
fibrosi
emphysema
especi
treatment
lung
cancer
follow
radiat
therapi
surgeri
particularli
high
risk
death
popul
sever
impair
ga
exchang
fact
chemotherapeut
agent
caus
acut
interstiti
pneumonia
subject
without
underli
respiratori
diseas
high
incid
seri
aeipf
occur
time
cours
diseas
may
also
mode
present
ipf
sever
retrospect
studi
evalu
clinic
characterist
patient
aeipf
mean
age
around
year
expect
ipf
patient
great
major
subject
present
dyspnea
sever
hypoxemia
fever
cough
flulik
symptom
present
medic
histori
focu
smoke
habit
toxic
exposur
prescrib
medic
physic
find
includ
tachypnea
cyanosi
digit
club
bilater
inspiratori
crackl
edema
lower
extrem
shortterm
prognosi
dismal
median
surviv
month
onset
ae
great
heterogen
degre
pulmonari
function
impair
time
ipf
diagnosi
need
supplement
oxygen
use
corticosteroid
immunosuppress
drug
prior
acut
event
degre
hypoxemia
present
mani
patient
show
sever
respiratori
failur
would
theoret
elig
mechan
ventil
highresolut
comput
tomographi
hrct
characterist
find
aeipf
newonset
ground
glass
opac
airspac
consolid
superimpos
underli
uip
pattern
differ
pattern
describ
higher
mortal
less
respons
therapi
subject
diffus
ground
glass
attenu
peripher
dissemin
patchi
opac
like
reflect
diseas
extent
rather
distinct
pathogen
process
fig
lung
patholog
aeipf
character
combin
underli
uip
pattern
associ
superimpos
acut
lung
injuri
diffus
alveolar
damag
fig
organ
pneumonia
featur
addit
aeipf
pattern
diffus
alveolar
damag
observ
patient
adult
respiratori
distress
syndrom
ard
syndrom
associ
differ
diagnos
known
caus
sepsi
pneumonia
trauma
idiopath
acut
interstiti
pneumonia
distinct
entiti
also
character
rapidli
progress
hypoxemia
mortal
proven
treatment
survivor
aeipf
usual
good
longterm
prognosi
similar
ard
survivor
experi
recurr
chronic
progress
function
deterior
acut
exacerb
independ
prognost
factor
ipf
half
ae
event
lethal
mortal
greater
patient
requir
ventilatori
assist
current
criteria
aeipf
found
tabl
diagnosi
requir
rule
variou
potenti
caus
clinic
worsen
includ
especi
lung
infect
pulmonari
embol
left
heart
failur
caus
acut
respiratori
distress
syndrom
may
easili
identifi
due
clinic
context
chest
hrct
key
assess
parenchym
abnorm
new
occurr
ground
glass
attenu
superimpos
underli
uip
pattern
ground
glass
attenu
may
inde
hallmark
underli
process
diffus
alveolar
damag
develop
set
ongo
fibroprolif
process
howev
specif
aeipf
also
relat
infect
ct
pulmonari
angiographi
gold
standard
diagnos
pulmonari
embol
perform
workup
ipf
patient
unexplain
rapidli
develop
respiratori
failur
rule
pulmonari
embol
rule
infect
patient
suspect
aeipf
challeng
aeipf
may
follow
genuin
episod
infect
tempor
overlap
two
condit
may
occur
attempt
made
identifi
bacteria
opportunist
pathogen
respiratori
virus
respiratori
sampl
keep
mind
neg
microbiolog
exclud
possibl
infect
noninvas
molecular
method
includ
urinari
antigen
pneumonia
legionella
well
blood
cultur
sputum
cultur
gener
indic
perform
bronchoscopi
bronchoalveolar
lavag
use
exclud
caus
acut
respiratori
failur
especi
infect
often
difficult
imposs
perform
due
sever
dyspnea
acut
respiratori
failur
yield
diagnosi
aeipf
therefor
benefit
risk
balanc
bronchoscopi
must
care
evalu
individu
level
diagnost
approach
aeipf
particularli
appropri
algorithm
rule
infect
diagnos
aeipf
earli
topic
review
intern
level
provid
better
guidanc
clinician
transthorac
echocardiographi
definit
use
exclud
congest
heart
failur
possibl
caus
acut
clinic
deterior
may
reveal
indirect
sign
pulmonari
hypertens
although
openlung
biopsi
could
secur
diagnosi
aeip
describ
contraind
case
aeipf
suspect
diagnosi
openlung
biopsi
might
consid
follow
care
benefit
risk
assess
subject
requir
mechan
ventil
intub
diffus
parenchym
lung
diseas
yet
rule
preexist
ipf
diagnos
prior
ae
case
uip
pattern
discov
lung
biopsi
along
diffus
alveolar
damag
organ
pneumonia
pattern
limit
evid
regard
best
diagnost
approach
sever
assess
aeipf
nevertheless
conceiv
diagnos
aeipf
earli
stage
might
allow
better
workup
diagnost
procedur
result
improv
outcom
therefor
time
accur
approach
hrct
warrant
patient
ipf
rapid
worsen
dyspnea
may
also
allow
better
understand
natur
cours
aeipf
see
fig
recent
trial
demonstr
efficaci
two
antifibrot
drug
reduc
declin
lung
function
patient
ipf
hope
new
treatment
chronic
progress
ipf
also
translat
reduc
occurr
aeipf
inde
nintedanib
act
tripl
tyrosin
kynas
inhibitor
abl
reduc
annual
rate
declin
fvc
patient
ipf
fvc
greater
predict
valu
carbon
monoxid
diffus
capac
compris
predict
increas
time
first
adjud
aeipf
prespecifi
sensit
analysi
pool
data
consist
earlier
find
provid
proofofconcept
drug
therapi
prevent
deadli
event
doubl
blind
random
control
trial
evalu
pirfenidon
versu
placebo
aeipf
event
occur
exclus
placebo
group
prompt
earli
termin
studi
number
aeipf
time
clinic
worsen
includ
aeipf
significantli
differ
patient
receiv
pirfenidon
placebo
phase
iii
trial
although
pirfenidon
significantli
reduc
declin
fvc
time
improv
surviv
year
futur
therapeut
strategi
protect
respiratori
epithelium
evalu
gastroesophag
reflux
treat
activ
even
asymptomat
clinic
trial
need
evalu
whether
treatment
reflux
may
reduc
risk
aeipf
current
treatment
demonstr
efficaci
aeipf
therefor
evidencebas
manag
strategi
part
due
lack
consist
approach
aeipf
base
pathogenesi
well
lack
random
control
trial
challeng
conduct
unpredict
onset
rapid
worsen
howev
group
use
highdos
corticosteroid
follow
intern
guidelin
base
expert
opinion
weak
posit
recommend
recommend
type
dose
durat
steroid
use
immunosuppress
therapi
may
combin
corticosteroid
puls
sever
case
yet
clear
evid
efficaci
use
immunosuppress
therapi
gener
consist
intraven
puls
cyclophosphamid
cyclosporin
tacrolimu
sometim
prefer
cyclophosphamid
base
small
studi
asia
suggest
improv
surviv
anticoagul
therapi
suggest
improv
surviv
patient
ipf
partli
due
effect
aeipf
eventu
prove
deleteri
use
treat
condit
altern
strategi
target
activ
coagul
cascad
includ
administr
recombin
human
thrombomodulin
retrospect
studi
show
encourag
result
overal
evid
current
lack
support
particular
drug
aeipf
sever
small
studi
suggest
potenti
benefici
effect
polymyxin
bimmobil
fiber
column
pmx
hemoperfus
treatment
patient
aeipf
possibl
adsorpt
proinflammatori
profibrot
proangiogen
cytokin
onto
pmx
although
studi
suffer
retrospect
noncontrol
design
heterogen
support
hypothesi
extracorpor
techniqu
might
benefici
studi
current
ongo
use
plasma
exchang
patient
aeipf
combin
corticosteroid
rituximab
wwwclinicaltrialsgov
due
difficulti
differenti
idiopath
aeipf
bronchopulmonari
infect
occur
cours
ipf
potenti
overlap
broadspectrum
antibiot
often
administ
subject
acut
worsen
dyspnea
mani
aeipf
patient
develop
acut
respiratori
failur
outcom
mechan
ventilatori
support
use
dismal
vast
major
patient
die
intens
care
unit
followup
period
decis
intub
gener
taken
especi
infect
potenti
confound
factor
rule
howev
small
subset
patient
might
elig
lung
transplant
case
aggress
approach
intens
care
unit
consid
interestingli
extracorpor
membran
oxygen
ecmo
abl
use
success
bridg
lung
transplant
patient
acut
respiratori
failur
refractori
intervent
retrospect
studi
ecmo
use
mean
day
rang
day
nine
patient
transplant
eight
aliv
year
transplant
encourag
experi
highlight
organ
care
earli
inclus
transplant
list
potenti
candid
paramount
offer
potenti
lifesav
intervent
event
aeipf
studi
avail
end
life
care
ipf
aeipf
current
approach
extrapol
endstag
condit
lung
cancer
endstag
respiratori
failur
even
import
consid
aeipf
patient
sedat
intub
therefor
rel
expos
dramat
pain
symptom
experi
palliat
dyspnea
anxieti
gener
manag
opioid
benzodiazepin
respiratori
depress
obvious
problem
therefor
open
discuss
patient
rel
mandatori
explain
aim
palliat
recent
demonstr
ongo
discuss
uk
end
life
treatment
also
manag
cough
import
use
variou
type
drug
palliat
symptom
limit
data
avail
regard
noninvas
mechan
ventil
use
spontaneoustim
mode
continu
posit
airway
pressur
cpap
mode
might
use
palliat
short
breath
summari
manag
strategi
potenti
use
variou
stage
aeipf
avail
tabl
although
signific
progress
made
recent
better
evalu
diseas
progress
ipf
ae
remain
unpredict
caus
rapid
deterior
dyspnea
lung
function
high
risk
death
associ
signific
psycholog
distress
patient
rel
despit
progress
made
awar
physician
regard
dramat
event
diagnos
aeipf
remain
challeng
especi
boundari
idiopath
aeipf
infect
still
unclear
requir
studi
highlight
best
flow
chart
diagnost
clinic
manag
furthermor
manag
complic
lack
effect
pharmacolog
treatment
current
approach
base
empir
attempt
similar
ard
conduct
clinic
trial
aeipf
challeng
need
address
rel
aeipf
event
observ
recent
ipf
clinic
trial
indic
larg
sampl
size
requir
captur
potenti
reduct
incid
aeipf
subject
receiv
antifibrot
agent
aim
reduc
chronic
diseas
progress
howev
studi
conduct
specif
evalu
therapeut
approach
patient
present
confirm
episod
aeipf
larg
network
patient
clinician
need
assess
efficaci
therapeut
intervent
take
account
influenc
confound
factor
better
guidanc
physician
need
adapt
investig
criteria
often
sever
manifest
limit
diagnost
procedur
intern
guidelin
current
revis
aim
provid
realist
diagnost
criteria
base
noninvas
procedur
account
current
limit
diagnosi
manag
develop
valid
biomark
longstand
object
field
remain
area
research
biomark
may
contribut
variou
aspect
diseas
cours
includ
earli
diagnosi
assess
rate
progress
diseas
differenti
infect
idiopath
diseas
predict
respons
therapi
improv
understand
etiolog
epidemiolog
prevent
measur
potenti
risk
factor
clinic
predictor
need
novel
drug
especi
tyrosin
kinas
inhibitor
target
epiderm
growth
factor
receptor
egfr
associ
high
risk
ild
exacerb
clinician
exert
particular
scrutini
use
wide
spectrum
new
biolog
drug
enter
clinic
practic
oncolog
ipf
correl
higher
risk
develop
cancer
whether
next
antitumor
agent
increas
risk
exacerb
unknown
continu
postmarket
surveil
need
detect
potenti
effect
new
drug
natur
histori
ipf
acut
exacerb
ipf
ild
one
challeng
year
come
doctor
work
difficult
group
diseas
goal
clinic
research
field
provid
tool
possibl
evidencebas
guidanc
identifi
therapi
prevent
treat
aeipf
